Sonnet Biotherapeutics Holdings Inc
Change company Symbol lookup
Select an option...
SONN Sonnet Biotherapeutics Holdings Inc
MDXG MiMedx Group Inc
CATY Cathay General Bancorp
EADSF Airbus SE
ARAY Accuray Inc
TGI Triumph Group Inc
TSNP Tesoro Enterprises Inc
BLV Vanguard Long-Term Bond Index Fund ETF Shares
BP BP PLC
$RFTREES Refinitiv Eurozone ESG Select Index
Go

Company profile

Sonnet Biotherapeutics Holdings Inc, formerly Chanticleer Holdings, Inc., an oncology-focused biotechnology company. The Company is developing targeted biologic drugs with enhanced single or bispecific mechanisms.

Closing Price
$2.46
Day's Change
0.09 (3.80%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.51
Day's Low
2.34
Volume
(Light)
Volume:
592,946

10-day average volume:
843,940
592,946

Latest Earnings (Year ending 12/2019)

--
Consensus estimate
--

Latest Earnings Estimate Range

Highest
estimate
--
Mean
estimate
--
Lowest
estimate
--

Annual Consensus Estimates and Ranges

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.